Tullis Health Investors

Tullis concentrates on companies that sell to the healthcare system—hospitals, payers, and physicians—rather than consumer-facing health products. The firm focuses on revenue-stage businesses with existing reimbursement coverage in sectors including medical devices, diagnostics, healthcare IT, and outsourced services. The firm explicitly avoids early-stage biotech and any sector dependent on direct-to-consumer marketing.

Tullis operates through a conventional private equity fund structure, raising committed capital from institutional limited partners for direct investments. The firm leads growth equity and recapitalization rounds rather than operating as a fund-of-funds. Specific fund sizes and LP composition have not been publicly disclosed.

The firm maintains a low public profile, and individual investment committee members have not been widely named in public disclosures. The principals are understood to combine private equity experience with operational backgrounds in hospital administration and healthcare services. This operational DNA is what the firm cites as its primary differentiator when evaluating potential portfolio companies.

Tullis invests across expansion, late-stage growth, and turnaround situations within the healthcare sector. The common thread is that portfolio companies must have revenue, established reimbursement pathways, and a business model dependent on institutional healthcare buyers. The firm does not invest in seed, pre-revenue, or purely regulatory-approval-dependent pharmaceutical assets.

The firm's sourcing advantage comes from a concentrated network within hospital administration, payer organizations, and the specialized intermediaries who serve healthcare services companies. By investing exclusively in institutional-facing healthcare for multiple fund cycles, Tullis has built referral relationships with the executives who run these businesses—a network that diversified generalist funds cannot replicate without a dedicated sector focus.